Selnoflast

Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease[1][2][3].

Product Specifications

CAS Number

[2260969-36-4]

Product Name Alternative

Somalix; RO-7486967; IZD334

UNSPSC

12352005

Target

Interleukin Related; NOD-like Receptor (NLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/selnoflast.html

Purity

99.46

Solubility

1M NaOH : 3.33 mg/mL (adjust pH to 12 with 1M NaOH) |DMSO : 5 mg/mL (ultrasonic; adjust pH to 8 with 1M NaOH)

Smiles

O=C(NS(=O)(C1CCN(CC1)CC)=O)NC2=C(CCC3)C3=CC4=C2CCC4

Molecular Formula

C20H29N3O3S

Molecular Weight

391.53

References & Citations

[1]Vande Walle L, et al. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2023 Nov 29.|[2]Klughammer B, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med. 2023 Nov;13 (11) :e1471. |[3]Silvis MJM, et al., NLRP3-Inflammasome Inhibition with IZD334 Does Not Reduce Cardiac Damage in a Pig Model of Myocardial Infarction. Biomedicines. 2022 Nov 28;10 (12) :3056.